20 results about "Medetomidine" patented technology

This invention relates to a medemididine hapten, a complete antigen, and their preparation methods and applications. The structure of the medemididine hapten is shown in Formula I. The preparation method of the medemididine hapten includes: (1) substituting medemididine with ethyl 3-bromopropionate to obtain intermediate 2; (2) adding sodium hydroxide to deprotect the ester group to obtain medemididine hapten 3. The structure of the complete antigen is shown in Formula II. The preparation method of the complete antigen includes: coupling the medemididine hapten with a carrier protein to obtain the complete antigen. This invention discloses a method for preparing medemididine hapten and complete antigen. The synthesis steps are simple and effective, and it can be used in immunoassay. Among them, colloidal gold immunochromatography is simple to operate, has a short detection time, high specificity, and good reproducibility, which can meet the domestic demand for immunoassay of medemididine.

The application provides a dexmedetomidine hydrochloride soluble microneedle; the dexmedetomidine hydrochloride soluble microneedle comprises a substrate and a drug-loaded needle body, the drug-loaded needle body comprises dexmedetomidine hydrochloride and a penetration enhancer; the penetration enhancer comprises at least two of laurocapram, polyvinylpyrrolidone and polysorbate; the weight average molecular weight of the polyvinylpyrrolidone is 2000 Da to 13000 Da. The dexmedetomidine hydrochloride soluble microneedle provided by the application can significantly improve the peak drug concentration after transdermal delivery under the promotion of the penetration enhancer, has a short onset time and a long duration, and can achieve the effects of rapid release, rapid onset and sustained effectiveness.

The invention relates to a dexmedetomidine film agent and a preparation method thereof, the prescription components of the dexmedetomidine film agent comprise dexmedetomidine or a pharmaceutically acceptable salt thereof and a film-forming agent, and the mass ratio of dexmedetomidine to the film-forming agent is 1: (20-200); the film-forming agent is glucose polymer ether. The glucose polymer ether can be a cellulose ether derivative and / or a starch ether derivative. When the glucose polymer ether is a starch ether derivative, the formula further comprises a plasticizer. The preparation method comprises the following steps: coating slurry to prepare a film, and drying; the slurry comprises the prescription components of the dexmedetomidine and water. And the obtained film agent product is stable in quality.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention provides a dexmedetomidine transdermal patch which comprises a backing layer, a release film and a polymer matrix layer arranged between the backing layer and the release film, the polymer matrix layer comprises dexmedetomidine, povidone and a pressure-sensitive adhesive, based on the total mass of the polymer matrix layer, the dexmedetomidine accounts for 4-10%, the povidone accounts for 5-10%, and the pressure-sensitive adhesive accounts for 5-10%. The povidone accounts for 2-12%, and the pressure-sensitive adhesive accounts for 78-94%; the pressure-sensitive adhesive comprises at least one of polymers containing carboxyl or hydroxyl functionalization.

A preparation method of an external patch for preoperative sedation relates to the field of medical preparations containing organic effective components, and sequentially comprises the steps of preparing a main component pretreatment substance, preparing a matrix solution, preparing an ointment-containing paste and synthesizing the patch, the preparation method of the main component pretreatment substance comprises the following steps: preparing a mixed liquid by taking dexmedetomidine hydrochloride and floperidol as main components, carrying out spray granulation to obtain a composite solid dispersion, crushing the composite solid dispersion into powder, and mixing and stirring the powder with paraffin oil and superfine silica powder. In the patch prepared from dexmedetomidine hydrochloride and floperidol, the effective components can quickly penetrate through the skin mucous membrane, so that the effect of quickly taking effect is achieved, and a good sedative effect is achieved. The dispersion uniformity of main components in the patch is excellent, the RSD is within 2%, and the effect consistency of the patch is guaranteed. According to the dexmedetomidine hydrochloride tablet, the stability of dexmedetomidine hydrochloride is effectively improved, components are prevented from being decomposed in the long-term storage process, other impurities are not generated, and the shelf life is effectively prolonged to 24 months.

A superhydrophobic anti-fouling crayon comprises a composition of capsaicin, wax, polydimethylsiloxane (PDMS), polytetrafluoroethylene (PTFE), and triglyceride, where the crayon is water insoluble, superhydrophobic, and transparent to electronic sensor and antennae signals. The crayon is rubbed onto the marine surface such that a layer of the composition of the crayon is applied thereto to produce a durable coating that inhibits fouling.

The present disclosure relates to a dexmedetomidine microneedle patch, a method for preparing the same, and application thereof. The dexmedetomidine microneedle patch includes a substrate and a needle body disposed on a surface of the substrate, wherein the needle body includes dexmedetomidine hydrochloride, a matrix material, and a permeation enhancer. The permeation enhancer includes one or more of dodecyl-β-D-maltoside, ethylenediaminetetraacetic acid, and tetrahydropiperine.

This application relates to the use of dexmedetomidine in the preparation of a drug for protecting the glycocalyx structure of lung tissue, a formulation thereof, and its application, belonging to the field of lung injury technology. This application provides a formulation for protecting the glycocalyx structure of lung tissue, the formulation containing dexmedetomidine, which can protect the glycocalyx structure of lung tissue, thereby reducing lung injury and can be used to treat lung injury.

The present disclosure relates to methods of using dexmedetomidine for therapeutic purposes wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at least once a day for at least two consecutive days.

The invention belongs to the technical field of anesthetic drugs, and particularly relates to an anesthetic drug and a preparation method thereof. The anesthetic is prepared by mixing 1000 parts by weight of bupivacaine liposome injection, 0.5-1 part by weight of magnesium sulfate and 3-5 parts by weight of dexmedetomidine hydrochloride. Wherein magnesium sulfate and dexmedetomidine hydrochloride are auxiliary agents, so that the anesthesia onset time is shortened. The anesthetic prepared by the invention is smaller in side effect, quick in effect taking and long in maintenance time, the injection frequency of the anesthetic can be reduced, the infection risk and the nursing cost can be reduced, the anesthetic effect is good, and the application prospect is wide.

The present invention relates to a method for the production of a liquid formulation suitable for intravenous administration in a glass vial with a rubber stopper, where the formulation is dexmedetomidine hydrochloride in water for injection (WFI). The method comprises steps of introducing WFI into a preparation vessel, passing an inert gas through the WFI until a dissolved oxygen content of 1 ppm or less is obtained, adding and dissolving a quantity of sodium chloride and dexmedetomidine hydrochloride, filtering the dexmedetomidine hydrochloride solution, and filling one or more glass vials with the liquid dexmedetomidine hydrochloride-in-WFI formulation before closing said vials with a rubber stopper and sealing the vials. The invention also relates to a sterile liquid formulation of dexmedetomidine hydrochloride in WFI, and its applications.

The application discloses application of Phillygenin combined with dexmedetomidine in improving myocardial ischemia-reperfusion injury and belongs to the technical field of drug development. The drug composition is composed of Phillygenin and dexmedetomidine; the combined use of Phillygenin and dexmedetomidine can reduce myocardial ischemia-reperfusion injury, and compared with the use of Phillygenin or dexmedetomidine alone, the combined use of Phillygenin and dexmedetomidine has a synergistic effect. The combined use of Phillygenin and dexmedetomidine can prevent and treat myocardial ischemia-reperfusion injury and provides a new target for the treatment of myocardial ischemia-reperfusion.

Methods and compositions, e.g., compositions for intravenous administration, comprising dextroamphetamine and / or lisdexamfetamine for use in reversal of dexmedetomidine sedation.

This invention relates to the field of healthcare informatics technology and discloses a dexmedetomidine MDK-mediated pathway network inference system. The system comprises a data acquisition module that receives infusion sequences, pressure monitoring streams, and biochemical data; a time feature alignment unit that identifies infusion jump characteristics to establish the physical excitation origin and calculates pressure response delay to determine communication latency; a dynamic phase calibration module that performs time-domain translation based on this latency and extracts the elastic phase deviation of metabolic lag through cross-correlation calculations; and a regulatory topology construction module that eliminates time offsets between monitoring data and calculates causal weights to establish the regulatory pathway topology. This invention uses physical calibration to eliminate communication latency interference from devices, achieving precise phase locking at the physiological level, resolving inference errors caused by clock offsets, enhancing recognition accuracy under low signal-to-noise ratios, and providing accurate pathway feedback maps for clinical decision-making.

Aspects of the invention include methods of managing pain in a subject by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver a pain relieving effective amount of dexmedetomidine to a subject. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine effective to manage pain in the subject. In some embodiments, methods include hydrating the subject, such as by administering a hydration fluid composition to the subject. Methods according to certain embodiments may also include co-administering an opioid to the subject. Also provided is a transdermal delivery device configured to deliver dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery device.

The present embodiments relate to a method for reducing or preventing attacks from marine woodborers on wood in marine environment by impregnating the wood with a composition comprising medetomidine, or an enantiomer, salt or base thereof.

The invention relates to a racemization method of dexmedetomidine hydrochloride resolution byproducts, which comprises the following steps: converting mother liquor (containing a large amount of optical levomedetomidine and dexmedetomidine) after dexmedetomidine resolution into racemized medetomidine, and further splitting to obtain dexmedetomidine hydrochloride. According to the invention, waste levomedetomidine is converted into dexmedetomidine hydrochloride again, the method has great significance for controlling the production cost of the dexmedetomidine hydrochloride bulk drug, and the preparation method has the advantages of being simple, mild in condition and suitable for industrial production.

The invention provides a dexmedetomidine hydrochloride soluble microneedle. The dexmedetomidine hydrochloride soluble microneedle comprises a substrate and a medicine carrying needle body, wherein the medicine carrying needle body contains dexmedetomidine hydrochloride and a penetration enhancer; the penetration enhancer is prepared from at least two of laurocapram, polyvinylpyrrolidone and polysorbate; the weight-average molecular weight of the polyvinylpyrrolidone ranges from 2,000 Da to 1,3,000 Da. According to the dexmedetomidine hydrochloride soluble microneedle provided by the invention, the peak concentration of a drug delivered percutaneously under the promotion action of the penetration enhancer is obviously improved, the onset time is short, the duration time is long, and the effects of quick release, quick onset and continuous effectiveness can be achieved.

The invention discloses a double-drug co-delivery lipidosome and a preparation method and application thereof, and belongs to the technical field of biological medicine, the double-drug co-delivery lipidosome is prepared from the following raw materials: DSPC, DSPE-PEG2K, cholesterol, DSPE-PEG2K-ANG2, DSPE-PEG2K-COG1410 and dexmedetomidine, the mass ratio of the DSPC to the cholesterol to the DSPE-PEG2K to the DSPE-PEG2K-ANG2 to the DSPE-PEG2K-COG1410 to the dexmedetomidine is (28-32): (8-12): (4-6): (2-3): (2-3): (0.4-0.6), the particle size of the lipidosome is 150-200nm, and the The composite nano-drug has the surface potential of 0 to-30 mV, belongs to a composite nano-drug system which has the BBB-crossing capability and regulates and controls microglial cells and neurons, and overcomes the limitation of the existing perioperative neurocognitive dysfunction combined anxiety therapy.